Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024		Dec. 31, 2023	Dec. 31, 2022
Statement of Cash Flows [Abstract]
Net earnings (loss)	$ (1,514)		$ 1,964	$ 1,902
Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities
Asset impairments	1,639	[1]	15	14
Depreciation, amortization and accretion	823		739	478
Pension and postretirement net periodic benefit cost	6		13	(85)
Pension and postretirement contributions	(54)		(49)	(48)
Actuarial (gain) loss on pension and postretirement plans	37		66	81
Pension curtailments and settlements, net	(9)		1	0
Deferred income taxes, net	216		(967)	(835)
(Gain) loss on disposition of businesses and assets, net	13		(501)	(8)
Stock-based compensation	32		40	60
Undistributed earnings in unconsolidated affiliates	(33)		55	(3)
Other, net	19		9	11
Operating cash provided by (used in) discontinued operations	(5)		(2)	(28)
Changes in operating assets and liabilities
Trade receivables - third party and affiliates, net	92		105	218
Inventories	11		398	(253)
Other assets	(10)		277	(13)
Trade payables - third party and affiliates	(234)		20	(84)
Other liabilities	(63)		(284)	412
Net cash provided by (used in) operating activities	966		1,899	1,819
Investing Activities
Capital expenditures on property, plant and equipment	(435)		(568)	(543)
Acquisitions, net of cash acquired	0		52	(10,589)
Proceeds from sale of businesses and assets, net	0		480	48
Settlement of cross-currency swap agreement	17		0	0
Other, net	(52)		(98)	(57)
Net cash provided by (used in) investing activities	(470)		(134)	(11,141)
Financing Activities
Net change in short-term borrowings with maturities of 3 months or less	15		(278)	36
Proceeds from short-term borrowings	160		452	500
Repayments of short-term borrowings	(418)		(603)	0
Proceeds from long-term debt	328		3,001	10,769
Repayments of long-term debt	(1,033)		(3,660)	(526)
Purchases of treasury stock, including related fees	0		0	(17)
Stock option exercises	1		0	0
Common stock dividends	(307)		(305)	(297)
Distributions/dividends to noncontrolling interests	(33)		(11)	(13)
Issuance cost of bridge facility	0		0	(63)
Other, net	(26)		(52)	(99)
Net cash provided by (used in) financing activities	(1,313)		(1,456)	10,290
Exchange rate effects on cash and cash equivalents	(26)		(12)	4
Net increase (decrease) in cash and cash equivalents	(843)		297	972
Cash and cash equivalents as of beginning of period	1,805		1,508	536
Cash and cash equivalents as of end of period	$ 962		$ 1,805	$ 1,508

[1] Primarily related to non-cash impairment losses on goodwill and certain trade names, primarily Zytel®, arising from the Company's goodwill and indefinite-lived intangible assets impairment tests (Note 9).